Product image of Nasofan (Fluticasone Propionate) supplied by GNH India

Nasofan

Active Ingredient:
Fluticasone Propionate
Origin:
EU

Nasofan (Fluticasone Propionate)

Fluticasone Propionate, the active ingredient in Nasofan, is a corticosteroid presented as a nasal spray for endosinusial use. It reduces nasal inflammation through local glucocorticoid activity and alleviates symptoms of allergic rhinitis and other nasal inflammatory disorders in both adults and children seasonally worldwide effectively.

GNH India supplies Nasofan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, ensuring product integrity from manufacture to end‑user.

Manufacturer / TM Owner

Teva Czech Industries S.R.O

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Fluticasone Propionate nasal glucocorticoid acts locally on the nasal mucosa to control inflammatory conditions.

  • Allergic rhinitis: reduces nasal congestion, sneezing, itching and rhinorrhoea associated with seasonal or perennial allergies.
  • Nasal polyposis: helps shrink polyps and improves nasal airflow in patients with chronic sinus disease.
  • Non‑allergic rhinitis: alleviates nasal irritation and discharge caused by irritant or vasomotor triggers.

How It Works

  • Fluticasone propionate binds to intracellular glucocorticoid receptors in nasal epithelial cells, altering gene transcription to suppress pro‑inflammatory cytokine production, inhibit mast cell degranulation, and reduce vascular permeability, thereby decreasing swelling and mucus formation in the nasal mucosa.

Side Effects

Fluticasone propionate is generally well tolerated, but adverse reactions can occur.

Common Side Effects

  • Nasal irritation or burning sensation.
  • Epistaxis (nosebleeds).
  • Headache.
  • Sore throat or hoarseness.
  • Altered taste or smell.

Serious or Rare Side Effects

  • Adrenal suppression with prolonged high‑dose use.
  • Cataract formation or glaucoma.
  • Severe allergic reaction (anaphylaxis).
  • Opportunistic fungal infection of the nasal passages.
  • Nasal septum perforation (very rare).

Precautions & Warnings

Before initiating therapy, consider the following precautions.

  • Assess for active nasal infection: avoid use until infection resolves.
  • Hypersensitivity: discontinue if patient shows allergic reaction to fluticasone or formulation components.
  • Use lowest effective dose: limit exposure to reduce systemic absorption.
  • Monitor for signs of adrenal suppression, especially with long‑term or high‑dose therapy.
  • Avoid abrupt discontinuation: taper if therapy has been prolonged.
  • Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Avoid Interactions

Fluticasone propionate may interact with other medicines that affect corticosteroid metabolism or systemic effects.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure and risk of adrenal suppression.
  • Concurrent systemic corticosteroids: additive effect on hypothalamic‑pituitary‑adrenal axis.

Moderate Interactions (Monitor Closely)

  • Moderate CYP3A4 inhibitors (e.g., erythromycin, ritonavir): may modestly raise fluticasone levels.
  • Antifungal azoles (e.g., fluconazole): monitor for increased local effects.
  • Live vaccines: efficacy may be reduced; consider timing of vaccination.

Frequently Asked Questions

Nasofan contains fluticasone propionate, a nasal glucocorticoid indicated for the treatment of allergic rhinitis, nasal polyposis and other inflammatory conditions of the nasal passages. It works locally to relieve congestion, sneezing, itching and nasal discharge.

Fluticasone propionate binds to glucocorticoid receptors inside nasal mucosal cells, modifying gene transcription to suppress the release of inflammatory cytokines, reduce vascular permeability, and inhibit mast‑cell activation. This anti‑inflammatory action decreases swelling and mucus production in the nose.

The prescribed dose of Nasofan is determined by the treating clinician based on the patient’s age, severity of symptoms and response to therapy. The prescriber will provide specific instructions on the number of sprays per nostril and the frequency of use.

Safety data for fluticasone propionate in pregnancy and lactation are limited. Healthcare providers generally weigh the potential benefits against any possible risks before prescribing. Patients should discuss their individual situation with a qualified medical professional.

To order Nasofan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nasofan’s active ingredient, fluticasone propionate, is a high‑potency corticosteroid with minimal systemic absorption when used as directed. Compared with older agents such as beclomethasone, it often provides stronger local anti‑inflammatory effects with a lower risk of systemic side effects at equivalent doses.

Nasofan should be stored at room temperature, below 25 °C, in its original packaging. Keep the device away from moisture, heat and direct sunlight. Do not freeze the product, and ensure the spray tip remains clean to maintain dose accuracy.

Nasofan is administered as a nasal spray. The patient gently shakes the bottle, primes the spray if required, tilts the head slightly forward, inserts the nozzle into one nostril, and delivers the prescribed number of sprays while breathing in gently. The process is repeated in the other nostril if directed.

Serious risks, though uncommon, include adrenal suppression with prolonged high‑dose use, cataract or glaucoma development, severe allergic reactions (anaphylaxis), and opportunistic fungal infections of the nasal mucosa. Patients should report persistent nosebleeds, visual changes or signs of systemic steroid effects to their clinician.

Nasofan should be avoided in individuals with known hypersensitivity to fluticasone propionate or any component of the formulation. It is also contraindicated in patients with active untreated nasal infections, recent nasal surgery or trauma, and in those for whom systemic corticosteroid exposure is contraindicated.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Fluticasone Propionate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT